NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

ADAPT Transcatheter Aortic Valve Intervention (TAVI & Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI)

NCT05259241

UnknownNA

Sponsor: Erasmus Medical Center

Conditions: Transcatheter Aortic Valve Replacement, Percutaneous Coronary Intervention

Interventions: activated partial thrombin time

Countries: Netherlands

Rationale: The choice of antithrombotic regimen during TAVI and CTO PCI includes the use of unfractionated heparin. The accuracy of ACT in this setting is disputed. ACT has never been compared to a point-of-care aPTT test for monitoring anticoagulation during percutaneous cardiac interventions. Objective: The aim of the present study is to evaluate which point-of-care test (ACT or aPTT) gives the best correlation with the coagulation status in patients, defined with the anti-Xa measurement. Study design: A Single-center, prospective, observational study Study population: patients undergoing TAVI (Cohort A) or CTO PCI (Cohort B) in the Erasmus University Medical Center Main study parameters/endpoints: The main study endpoints are the correlation between the ACT and APTT point-of-care- tests and the coagulation status, defined as the laboratory anti-Xa measurement.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* All patients undergoing a TAVI-procedure
* All patients undergoing a CTO PCI procedure

Exclusion Criteria:

* none

Locations (1)

Rotterdam, South Holland, Netherlands